Recently, another universal influenza virus vaccine has been manufactured. It is a multi-epitope-based vaccine and it targeted the already tested conserved T and B cell epitopes of HA, NP, M2 and NP proteins of the virus. Furthermore, in-silico techniques such as molecular docking and MD simulations confirmed the immunogenicity of the developed vaccine and their optimal binding with TLR2-4. Therefore, the results of the study indicated that the universal influenza vaccines developed in the study has the required potential for combating the influenza A and B strains . Primary target for most of the influenza vaccines is hemagglutinin protein whereas secondary target is neuraminidase both of which are surface proteins. Recently, a novel version of NA surface protein i.e. NA-I has been generated via utilizing COBRA technique. NA-I is able to respond to different influenza virus strains which might be in pigs, humans as well as avian (birds). For testing purposes N1-I infected antigens were found to be affective to multiple strains of influenza virus i.e. avian flu, swine flu and more specifically older H1N1 strains. Moreover, mice that were protected with this vaccine were protected from the virus on exposure to multiple flu strains from different countries of the world and was crossprotective. Therefore, it could be inferred from the study that N1-I COBRA NA antigen is an effective universal influenza vaccine which has broadened the protection against different strains of viruses from different areas